<DOC>
	<DOCNO>NCT00473187</DOCNO>
	<brief_summary>X-linked hypophosphatemic rickets ( XLH ) characterize rickets , disproportionate short stature , impaired renal phosphate reabsorption vitamin D metabolism . Despite oral phosphate vitamin D treatment , child XLH demonstrate reduce adult height . The main objective study determine beneficial effect recombinant human growth hormone ( rhGH ) therapy body proportion 36 month patient . Secondary objective monitor side effect therapy .</brief_summary>
	<brief_title>Effects GH Body Proportions Final Height X-Linked Hypophosphatemic Rickets</brief_title>
	<detailed_description />
	<mesh_term>Growth Disorders</mesh_term>
	<mesh_term>Rickets</mesh_term>
	<mesh_term>Rickets , Hypophosphatemic</mesh_term>
	<mesh_term>Familial Hypophosphatemic Rickets</mesh_term>
	<criteria>Tanner stag puberty B1 , G1 body height &lt; 2,5 SDS growth velocity &lt; 75 % confirm diagnosis XLHR conservative treatment least 1 year ( phosphate , vitamin D ) inform consent , write agreement growth hormone deficiency hypothyreosis severe rickets severe physical deformity severe hyperparathyreoidism chronic renal failure complex syndrome involve failure thrive chronic disease failure thrive impairment glucose tolerance Tanner stag puberty great B1 , G1 medical history malignancy therapy growth hormone , glucocorticoides , anabolica attend another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>X-linked dominant hypophosphatemic rickets</keyword>
	<keyword>growth disorder</keyword>
	<keyword>anthropometry</keyword>
	<keyword>human growth hormone</keyword>
</DOC>